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Introduction: Although the molecular genetics possibly underlying 
the pathogenesis of human thymoma have been extensively studied, 
its etiology remains poorly understood. Because murine polyoma-
virus consistently induces thymomas in mice, we assessed the pres-
ence of the novel human polyomavirus 7 (HPyV7) in human thymic 
epithelial tumors.
Methods: HPyV7-DNA Fluorescence in situ hybridization (FISH), 
DNA-polymerase chain reaction (PCR), and immunohistochemistry 
(IHC) were performed in 37 thymomas. Of these, 26 were previously 
diagnosed with myasthenia gravis (MG). In addition, 20 thymic 
hyperplasias and 20 fetal thymic tissues were tested.
Results: HPyV7-FISH revealed specific nuclear hybridization sig-
nals within the neoplastic epithelial cells of 23 thymomas (62.2%). 
With some exceptions, the HPyV7-FISH data correlated with the 
HPyV7-DNA PCR. By IHC, large T antigen expression of HPyV7 
was detected, and double staining confirmed its expression in the 
neoplastic epithelial cells. Eighteen of the 26 MG-positive and 7 
of the 11 MG-negative thymomas were HPyV7-positive. Of the 20 
hyperplastic thymi, 40% were HPyV7-positive by PCR as confirmed 
by FISH and IHC in the follicular lymphocytes. All 20 fetal thymi 
tested HPyV7-negative.
Conclusions: The presence of HPyV7-DNA and large T antigen 
expression in the majority of thymomas possibly link HPyV7 to 
human thymomagenesis. Further investigations are needed to eluci-
date the possible associations of HPyV7 and MG.
Key Words: Human polyomavirus 7, thymomas, thymic follicular 
hyperplasia, viral tumorigenesis, myasthenia gravis
(J Thorac Oncol. 2015;10: 360–366)
The autoimmune disease myasthenia gravis (MG) has been associated with thymomas and follicular hyperplasia. 
Moreover, the role of viral infections has been implicated in 
this disease. There have been several studies on the molecular 
genetics possibly underlying the pathogenesis of thymomas, 
that is, epithelial thymic neoplasias admixed with a variable 
non-neoplastic lymphoid component.1,2 However, the etiol-
ogy of human thymoma remains poorly understood. Over the 
last two decades, the possible involvement of the oncogenic 
γ-herpesvirus Epstein-Barr (EBV) has proved debatable.3–7
Next to EBV, polyomaviral infection has been impli-
cated in the etiology of thymomas, based on the consistent 
finding that the polyomavirus strain PTA induces thymomas 
in mouse strains C3H/BiDa and AKR.8,9 Polyomaviruses are 
small circular double-stranded DNA viruses which have been 
extensively used to study cell transformation in vitro and 
tumorigenesis in animal models. In recent years, a number 
of new human polyomaviruses have been identified, giving a 
current total of 12.10–12 Yet, only the Merkel cell polyomavirus 
(MCPyV), discovered in 2008, has been identified as a new 
human tumor virus.13 MCPyV has been shown to be present 
in approximately 80% of Merkel cell carcinomas (MCCs), 
which are highly malignant neuroendocrine carcinomas of the 
skin.14,15 In these, MCPyV is clonally integrated in the tumor 
genome, and tumor-specific oncogenic mutations within the 
viral genome have been identified.13,16 Recently, polyomavi-
ruses 6 and 7 (HPyV6 and 7) have been isolated from skin 
samples and characterized, but have yet not been associated 
with any human disease.17 However, seroprevalence of HPyV 
6 and 7 indicates that infection is common in humans, that 
is, 69% and 35%.17 A recent study has shown that the serop-
revalence of HPyV7 reveals a regularly age-related increase, 
with less than 10% in the age group below 4 years and 
approximately 45% in the age group 10–14 years, reaching 
approximately 64% in adults.18 On the basis of an initial DNA 
polymerase chain reaction (PCR) screening testing for the 
presence of novel polyomaviruses in diverse human cancers, 
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we assessed the possible role of HPyV7 in human thymic epi-
thelial tumors and other thymic tissues.
MATERIALS AND METHODS
Patients and Tissues
Formalin-fixed and paraffin-embedded (FFPE) resection 
specimens were included in this study. All thymomas and two 
thymic carcinomas (19 female and 18 male; mean age 58.3 
years; range 34–82 years), and 20 fetal gestational thymic tis-
sues from fetus autopsies had been obtained for diagnostic and 
therapeutic reasons. So had 20 thymi with follicular hyperpla-
sia, 19 of them from patients with MG (15 females, 5 males, 
mean age 27.4 years), of which 17 with antiacetylcholine recep-
tor (AChR) antibodies and 4 receiving immunosuppressive 
therapy (steroids). Twenty-six thymoma patients were known 
with a history of MG, of which 23 were anti-AChR antibodies 
positive and 3 negative. Thirteen of the 26 MG-positive thy-
moma patients received immunosuppressive (steroids) therapy. 
Clinicopathological data of thymoma and hyperplastic thymi 
patients are summarized in Tables 1 and 2. All specimens were 
obtained from the Maastricht Pathology Tissue Collection. All 
use of tissue and patient data was in agreement with the Dutch 
Code of Conduct for Observational Research with Personal 
Data (2004) and Tissue (2001, www.fmwv.nl).
HPyV7 Detection by DNA PCR
Genomic DNA was isolated from whole FFPE tis-
sue sections using a DNA Isolation Kit (Qiagen, Hilden, 
Germany). DNA quality and integrity was first assessed by 
specimen control size ladder (Tables 1 and 2) as described19; 
we excluded any sample where it was inadequate. HPyV7 
DNA PCR was performed as described previously, using oli-
gonucleotides targeting the small T antigen (181 base pairs) 
and the large T antigen (LTAg) (112 base pairs).17,20
Detection of HPyV7 by Fluorescence 
In Situ Hybridization (FISH)
The HPyV7 full-length probe was obtained from 
Addgene, Cambridge, MA, and linearized. FISH was per-
formed on 3-μm-thick FFPE sections according to Hopman et 
al. with modifications.21 In brief, deparaffinized sections were 
incubated with 0.2 M HCl for 20 min (and washed in dH
2
O 
and 2× SSC), and then with 1 M NaSCN for 30 min at 80°C. 
After further washing, sections were digested with1 mg/ml 
pepsin (2500–3500 U/mg; Sigma Chemical, St. Louis, MO), 
pH 2. To test HPyV7-probe specificity, sections were first 
treated with 0.2 g/100 ml pepsin (Sigma) in 0.01 M HCl at 
37°C for 10 min and then with DNase I (Qiagen) for 30 min 
at 37°C with 5.7 U in RDD buffer (Qiagen), before cooling 
on ice, washing twice in 2× SSC, and postfixing in 4% form-
aldehyde. After washing in 2× SSC and rinsing in dH2O, the 
sections were dehydrated in an ascending ethanol series. The 
biotin-labeled HPyV7 probe was added under the coverslip at 
a concentration of 10 ng/μl in LCI/WCP buffer (Vysis, Abott, 
IL) together with 50× excess human COT-1 DNA (Vysis) 
and 50× tRNA from S. cerevisiae (Sigma). Denaturation of 
the probe and the target DNA was carried out simultaneously 
for 5 min at 80°C before hybridization overnight at 37°C in 
a humid chamber (Thermobrite, Abbott, IL). Unhybridized 
probe was stringently washed away from the preparations in 
2× SSC, pH 7.0 at 70°C for 2 min. The biotin (Bio)-labeled 
probe was detected with sequential incubations with fluo-
rescein isothiocyanate (FITC)-conjugated avidin (1:500; 
Vector, Brunswig Chemie, Amsterdam, The Netherlands), 
biotin-conjugated goat anti-avidin (1:100; Vector), and FITC-
conjugated avidin 1:500, all for 30 min at 37°C and diluted in 
Boehringer Blocking reagent (Roche). Finally, the slides were 
dehydrated in an ascending ethanol series and mounted in 0.2 
μg/ml DAPI-Vectashield (Vector Laboratories, CA). HPyV7 
FISH signals were detected using a DM 5000 B fluorescence 
microscope (Leica, Wetzlar, Germany) equipped with DAPI, 
TR (Texas red) and FITC filters. Images were recorded with a 
Leica DC 300 Fx camera (Leica). FISH fluorescence intensity, 
signal numbers, and sizes for strong and weak nuclear FISH 
signals were evaluated independently by five investigators 
(D.R., M.K., E.J.S., A.H., A.z.H.) according to the criteria in 
Hafkamp et al.22 After DNAse pretreatment (see above) of the 
slides of HPyV7 DNA positive cases, as assessed by PCR and 
sequencing, no specific nuclear HPyV7 hybridization signals 
were seen. In addition, specificity of the HPyV7 probe was 
assessed by the omission of the HPyV7 probe revealing no 
specific FISH hybridization signals in HPyV7 DNA positive 
skin and thymic tissues. Cross-hybridization with MCPyV 
was excluded by performing HPyV7 FISH on the MCPyV-
positive MKL1 cell line, which did not show any specific 
hybridization signals (Fig. S1).13
Immunohistochemistry (IHC) 
and Double Staining
The following antibodies and dilutions were used: anti-
Pancytokeratin AE1/3 (DAKO; Glostrup, Denmark; “Ready 
to use Antibody”); monoclonal antibody 2T10 against LTAg 
of HPyV7 was provided by C. Buck, NCI, Bethesda, and used 
at 1:100 with the EnVision FLEX™ visualization Kit K8008 
DAKO according to standard protocols. When FISH was fol-
lowed by IHC, the protocols were adapted slightly.
RESULTS
HPyV7 Detection in Thymic Epithelial 
Tumors by DNA PCR and FISH
Screening of diverse human cancers for the presence 
of novel polyomaviruses revealed that HPyV7 was frequently 
present in human thymomas but not HPyV6. (Fig. 1). Twenty 
(54%) of the 37 thymomas tested positive for HPyV7-DNA 
by PCR (Table 1). All PCR products were sequenced and con-
firmed the presence of HPyV7, with only minor nucleotide 
differences between them. One of the two thymic carcinomas 
was HPyV7-DNA positive and the other negative.
By FISH, HPyV7-specific nuclear hybridization signals 
were found in 23 thymomas (62.2%) (Fig. 2; summarized in 
Table 1). In these, 15 thymomas with strong to very strong 
specific nuclear hybridization signals and eight revealed weak 
positivity. In the thymomas with strong nuclear hybridization 
signals, almost all neoplastic cells were HPyV7-positive. They 
362 Copyright © 2014 by the International Association for the Study of Lung Cancer
Rennspiess et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015
were more heterogeneous in the eight with weaker signals. 
HPyV7-FISH and antipancytokeratine immunofluorescence 
double labeling confirmed that the specific nuclear hybridiza-
tion were mostly restricted to epithelial cells (Fig. 2); only in a 
few tumors was it also found in rare lymphocytes. HPyV7 did 
not correlate with any World Health Organization thymoma 
subtype (Table 1).
LTAg of HpyV7 is Highly Expressed 
in Human Thymomas
Marked LTAg expression was found by IHC in 17 
(46%) of the thymomas within the epithelial cells (Fig. 3A and 
B), but not always in every cell in the positive cases, unlike 
FISH. Overall, LTAg labeling was in good agreement with the 
HPyV7-DNA PCR and/or the HPyV7-FISH.
TABLE 1.   Summary of Clinicopathological Data and Results of Thymomas
Clinicopathological Data HPyV7








(112 bp) FISH IHC 2t10
1 1–1 F 73 + B1/B2 + + + + + + −
2 1–2 F 75 + B1/B2 + + + + + + −
3 1–3 F 57 + B2/B3 + − + + + + +
4 1–4 M 40 + B2 + + + + + + −
5 1–5 M 37 + B3 + + + + + ++ +
6 1–7 F 79 + A − − + + + ++ (+)
7 1–8 M 58 + A/B2 + − + + + +++ (+)
8 1–9 M 64 − B2 NA NA + + + ++ (+)
9 1–10 F 73 + B3 + + + − − − −
10 1–11 F 34 + B2 + − + − − ++ −
11 1–12 F 36 + A − + + − − − −
12 1–13 F 54 − B2 NA NA + − + + (+)
13 1–15 F 53 + B3 + + + − − + −
14 1–16 F 34 + A + + + − − − −
15 1–17 M 69 + AB + + + − + ++ −
16 1–18 F 47 + AB + + + + + − −
17 1–19 M 68 − AB NA NA + + + ++ +
18 1–20 M 64 − B3 NA NA + − − − −
19 1–21 F 38 + AB + − + − + − −
20 1–22 M 65 + AB/B2 + − + − − − −
21 1–23 M 37 + AB + − + + − + +
22 1–24 M 68 + B2 + − + + + ++ +
23 1–26 M 65 − AB NA NA + − − − −
24 1–28 M 38 − B1 NA NA + − − − −
25 1–30 M 37 + B2 + + + − − − −
26 1–31 F 82 + A + + + + + + +
27 1–32 M 47 + B2 + − + − − − −
28 1–33 F 43 + B2 + − + − − ++ +
29 1–34 M 59 - AB NA NA + + − ++ +
30 1–35 M 45 + AB + − + + + ++ +
31 1–36 F 82 − AB NA NA + − (+) ++ +
32 1–37 M 77 + AB + − + − − +++ (+)
33 1–38 F 80 + AB + + + − − − −
34 1–39 F 78 − B1 NA NA + − − − −
35 1–41 M 65 − B3 NA NA + + (+) +++ +
36 1–42 F 57 + AB + − + − − − −
37 1–43 F 78 − AB NA NA + − − ++ (+)
16/37 (43.2%) 18/37 (48.6%) 23/37 (62.2%) 17/37 (46%)
20/37 (54%) 23/37 (62.2%) 17/37 (46%)
Lab ID, laboratory identification; G., gender; MG, myasthenia gravis; Thym. type, thymoma type; anti-AChR, antiacetylcholine receptor antibodies; IS/Ster., immunosuppression/steroids; 
SCS ladder, specimen control size ladder; sTAg, small T antigen; LTAg, large T antigen; PCR, polymerase chain reaction; HPyV7, human polyomavirus 7; FISH, fluorescence in situ hybridization 
using full length HPyV7 as probe; IHC, immunohistochemistry using 2t10 monoclonal antibody directed against LTAg of HPyV7; +, positive; (+), weak positive; −, negative; NA, not applicable.
363Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015 Novel Human Polyomavirus 7 in Thymomas
Detection of HPyV7 in Thymic Follicular 
Hyperplasia DNA PCR and FISH
HPyV7-DNA was detected in 40% (n = 8) of the hyper-
plastic thymi. By HPyV7-FISH, the proportion of HPyV7-
positive cases reached 65% (n = 13). Importantly, specific 
nuclear HPyV7-hybridization signals were mostly restricted 
to scattered follicular B-cells, which possibly explain the dif-
ferent results of PCR and FISH. In six of these 20 hyperplastic 
thymi, IHC revealed mostly weak nuclear expression of the 
LTAg in some lymphoid cells in the follicles (Fig. 3C and D)
Association of HPyV7 and MG
Of the 26 patients with HPyV7-positive thymomas, 19 
were known to have MG. Of the 11 non-MG thymomas, seven 
were HPyV7-positive and four were HPyV7-negative (Table 1).
The only non-MG-hyperplastic thymus was 
HPyV7-positive.
HPyV 7 Is Not Detected in Fetal Thymus
Using HPyV7 DNA PCR, none of the fetal thymi, 
which were also tested for sufficient DNA quality and integ-
rity, tested positive for HPyV7.
DISCUSSION
With sophisticated new detection techniques, the num-
ber of novel human polyomaviruses has increased in the past 
6 years.23 However, of the 12 known human polyomaviruses, 
currently, only the MCPyV has been shown to be associated 
with a human cancer, that is, the MCC. Viral integration, 
tumor-specific viral mutations within the LTAg of MCPyV, 
and consistent epidemiology of MCPyV with MCC have led 
to the classification of MCPyV as a class 2A carcinogen by the 
International Agency for Research on Cancer.13–16,24
Here, we systematically assessed the presence of 
HPyV7 in human thymic epithelial tumors by diverse molec-
ular techniques.17 Focusing on different parts of the HPyV7 
genome, we found HPyV7-DNA in 54% of the 37 thymomas. 
At the single cell level, use of HPyV7-FISH demonstrated 
specific nuclear hybridization signals within the epithelial 
cells in 62.2% of the thymomas and only occasionally in 
lymphocytes. The discrepancies between the PCR and FISH 
results most likely reflect the varying proportions of positive 
cells in different tumors. Interestingly, however, thymomas 
1–37 and 1–43 (Table 1) gave strong hybridization signals in 
HPyV7 FISH plus weak IHC labeling for its LTAg despite 
negativity by HPyV7 PCR. Because we excluded technical 
reasons as far as possible, and also the presence of other 
known human polyomaviruses, these findings might hint 
at the presence of an as yet unidentified but closely related 
polyomavirus.
Our double labeling clearly showed that the great 
majority of the cells positive for viral DNA or protein 










(112 bp) FISH IHC 2t10
1 M 16 + + + + − − + −
2 F 15 + + − + − − + −
3 F 20 + + − + − + + −
4 F 25 + + − + − + − (+)
5 F 24 + + − + + − + (+)
6 F 26 + + − + + − + +
7 F 30 + + − + − − + −
8 F 32 + + − + − − + −
9 F 40 + + − + − − − −
10 F 13 + + − + + − + −
11 M 40 + + − + − + + (+)
12 F 34 + + − + − − − −
13 F 26 + + + + − − − (+)
14 F 24 + + − + − − + −
15 F 31 + + − + − − + −
16 F 22 + − + + − − − −
17 F 48 + + − + − − + (+)
18 M 39 + − + + − − + −
19 M 31 − NA NA + − + − (+)
20 M 12 + + − + + − + +
G, gender; MG, myasthenia gravis; anti-AChR, antiacetylcholine receptor antibodies; IS/Ster., immunosuppression/steroids; NA, not applicable; SCS ladder, specimen control 
size ladder; sTAg, small T antigen; LTAg, large T antigen; PCR, polymerase chain reaction; HPyV7, human polyomavirus 7; FISH, fluorescence in situ hybridization using full length 
HPyV7 as probe; IHC, immunohistochemistry using 2t10 monoclonal antibody directed against LTAg of HPyV7; +, positive; (+), weak positive; −, negative.
364 Copyright © 2014 by the International Association for the Study of Lung Cancer
Rennspiess et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015
expression of the HPyV7-LTAg in thymomas may hint at a 
role for HPyV7 in thymomagenesis. Although many other 
polyoma viral LTAg can act as oncogenes, no information 
is yet available about the oncogenic capacity of HPyV7. 
Notably, its LTAg was expressed quite strongly in some of 
the epithelial thymic tumors, especially compared with the 
variable numbers of HPyV7 LTAg lymphoid cells in thymic 
follicles (Fig. 3D).
In the hyperplastic thymi, HPyV7 DNA was detected 
by PCR in 40% and by FISH in 65%. The discrepancy can 
readily be explained by the number of cells detected by 
HPyV7-FISH, which varied over a wide range. By using 
HPyV7 FISH and an anti-HPyV7 LTAg monoclonal anti-
body, HPyV7-positivity was found to be largely restricted to 
follicular lymphoid rather than epithelial cells. That is in line 
with the known B lymphotropism of some human polyoma-
viruses.12,25,26 This finding is interesting because if HPyV7 
remains latently present in follicular B-cells, it could mean 
that it might be interesting to test also B-cell non-Hodgkin 
lymphomas for the presence of HPyV7. In addition, it may 
contribute to immunological alterations, which might initi-
ate or perpetuate immunological diseases such as MG as has 
recently been speculated for the oncogenic γ-herpesvirus 
Epstein-Barr (EBV).27 However, data on the finding of EBV 
in MG thymus are quite controversial, ranging between very 
high prevalence to almost not present.28,29 Although surpris-
ing that a highly reproducible standard routine testing for the 
presence of EBV (e.g., EBV-encoded RNAs, RNA in situ 
hybridization) in a histopathological lymphoma diagnostic 
setting fails the extent of reproducibility in the setting of MG 
thymus, it seems that further conclusive studies are needed to 
assess the role of EBV in MG thymi. The interesting recent 
finding of poliovirus in a subset of MG thymi needs to be 
independently confirmed.30
The fact that we did not find any HPyV7-positivity in 
gestational fetal thymic tissues reveals that HPyV7 infection 
occurs in the postnatal period and also indirectly leans support 
to a possible role for HPyV7 in human thymomagenesis in the 
context of the quite frequent finding within the epithelial cells 
of human thymic epithelial tumors.
In conclusion, this study is the first to demonstrate 
the presence and association of HPyV7 in thymic epithe-
lial tumors by diverse molecular techniques. Our failure 
to detect any signs of HPyV7 in fetal thymic tissues sug-
gests that HPyV7 reaches the thymus postnatal or later in 
life, which is in good agreement with the recent study on 
HPyV7 age related seroprevalence.18 Its contrasting 40%to– 
60% prevalence in thymomas also hints at a possible role for 
HPyV7 in their initiation, but requires independent confir-
mation in larger series.
Further studies would also be needed to assess the 
oncogenic potential of HPyV7, for example, viral integra-
tion, mutational analyses of the LTAg, and in vitro trans-
formation. Although HPyV7 is present in the majority of 
MG-associated thymomas, the numbers of cases investi-
gated in this study do not allow a conclusion on a possible 













365Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015 Novel Human Polyomavirus 7 in Thymomas
REFERENCES
 1. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (Eds.). 
Introduction in World Health Organization Classification of Tumours. 
Pathology and Genetics of Tumours of the Lung, Thymus and Heart. 
Lyon, France: IARC Press, 2004. Pp. 145–151.
 2. Ströbel P, Hohenberger P, Marx A. Thymoma and thymic carci-
noma: molecular pathology and targeted therapy. J Thorac Oncol 
2010;5:S286–S290.
 3. McGuire LJ, Huang DP, Teoh R, Arnold M, Wong K, Lee JC. Epstein-
Barr virus genome in thymoma and thymic lymphoid hyperplasia. Am J 
Pathol 1988;131:385–390.
 4. Borisch B, Kirchner T, Marx A, Müller-Hermelink HK. Absence of 
the Epstein-Barr virus genome in the normal thymus, thymic epithelial 
tumors, thymic lymphoid hyperplasia in a European population. Virchows 
Arch B Cell Pathol Incl Mol Pathol 1990;59:359–365.
 5. Inghirami G, Chilosi M, Knowles DM. Western thymomas lack Epstein-
Barr virus by Southern blotting analysis and by polymerase chain reac-
tion. Am J Pathol 1990;136:1429–1436.
 6. Engel PJ. Absence of latent Epstein-Barr virus in thymic epithelial tumors 
as demonstrated by Epstein-Barr-encoded RNA(EBER) in situ hybridiza-
tion. APMIS 2000;108:393–397.
 7. Chen PC, Pan CC, Yang AH, Wang LS, Chiang H. Detection of Epstein-
Barr virus genome within thymic epithelial tumours in Taiwanese patients 
by nested PCR, PCR in situ hybridization, and RNA in situ hybridization. 
J Pathol 2002;197:684–688.
 8. Wirth JJ, Fluck MM. Immunological elimination of infected cells as the 
candidate mechanism for tumor protection in polyomavirus-infected 
mice. J Virol 1991;65:6985–6988.
 9. Sanjuan N, Porrás A, Otero J, Perazzo S. Expression of major capsid pro-
tein VP-1 in the absence of viral particles in thymomas induced by murine 
polyomavirus. J Virol 2001;75:2891–2899.
 10. Van Ghelue M, Khan MT, Ehlers B, Moens U. Genome analysis of the 
new human polyomaviruses. Rev Med Virol 2012;22:354–377.
 11. Siebrasse EA, Reyes A, Lim ES, et al. Identification of MW polyomavi-
rus, a novel polyomavirus in human stool. J Virol 2012;86:10321–10326.
 12. DeCaprio JA, Garcea RL. A cornucopia of human polyomaviruses. Nat 
Rev Microbiol 2013;11:264–276.
 13. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyoma-
virus in human Merkel cell carcinoma. Science 2008;319:1096–1100.
 14. Kassem A, Schöpflin A, Diaz C, et al. Frequent detection of Merkel cell 
polyomavirus in human Merkel cell carcinomas and identification of a 
unique deletion in the VP1 gene. Cancer Res 2008;68:5009–5013.
 15. Becker JC, Houben R, Ugurel S, Trefzer U, Pföhler C, Schrama D. MC 
polyomavirus is frequently present in Merkel cell carcinoma of European 
patients. J Invest Dermatol 2009;129:248–250.
 16. Shuda M, Feng H, Kwun HJ, et al. T antigen mutations are a human 
tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad 
Sci U S A 2008;105:16272–16277.
 17. Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. Merkel 
cell polyomavirus and two previously unknown polyomaviruses are 
chronically shed from human skin. Cell Host Microbe 2010;7:509–515.
 18. Nicol JT, Robinot R, Carpentier A, et al. Age-specific seroprevalences of 
merkel cell polyomavirus, human polyomaviruses 6, 7, and 9, and tricho-
dysplasia spinulosa-associated polyomavirus. Clin Vaccine Immunol 
2013;20:363–368.
 19. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and stan-
dardization of PCR primers and protocols for detection of clonal 
immunoglobulin and T-cell receptor gene recombinations in suspect 
lymphoproliferations: report of the BIOMED-2 Concerted Action 
BMH4-CT98-3936. Leukemia 2003;17:2257–2317.
 20. Duncavage EJ, Pfeifer JD. Human polyomaviruses 6 and 7 are not detect-
able in Merkel cell polyomavirus-negative Merkel cell carcinoma. J 
Cutan Pathol 2011;38:790–796.
 21. Hopman AH, Kamps MA, Smedts F, Speel EJ, Herrington CS, Ramaekers 
FC. HPV in situ hybridization: impact of different protocols on the detec-



























366 Copyright © 2014 by the International Association for the Study of Lung Cancer
Rennspiess et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015
 22. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in sur-
vival rate between smokers and nonsmokers with HPV 16-associated ton-
sillar carcinomas. Int J Cancer 2008;122:2656–2664.
 23. Dalianis T. Immunotherapy for polyomaviruses: opportunities and chal-
lenges. Immunotherapy 2012;4:617–628.
 24. Bouvard V, Baan RA, Grosse Y, et al. Carcinogenicity of malaria and of 
some polyomaviruses. Lancet Oncol 2012;13:339–340.
 25. Toracchio S, Foyle A, Sroller V, et al. Lymphotropism of Merkel cell polyoma-
virus infection, Nova Scotia, Canada. Emerg Infect Dis 2010;16:1702–1709.
 26. Pantulu ND, Pallasch CP, Kurz AK, et al. Detection of a novel truncating 
Merkel cell polyomavirus large T antigen deletion in chronic lymphocytic 
leukemia cells. Blood 2010;116:5280–5284.
 27. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus per-
sistence and reactivation in myasthenia gravis thymus. Ann Neurol 
2010;67:726–738.
 28. Meyer M, Höls AK, Liersch B, et al. Lack of evidence for Epstein-
Barr virus infection in myasthenia gravis thymus. Ann Neurol 
2011;70:515–518.
 29. Kakalacheva K, Maurer MA, Tackenberg B, Münz C, Willcox N, 
Lünemann JD. Intrathymic Epstein-Barr virus infection is not a promi-
nent feature of myasthenia gravis. Ann Neurol 2011;70:508–514.
 30. Cavalcante P, Barberis M, Cannone M, et al. Detection of poliovirus-
infected macrophages in thymus of patients with myasthenia gravis. 
Neurology 2010;74:1118–1126.
